546 related articles for article (PubMed ID: 32801017)
1. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
2. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Mersiades AJ; Tognela A; Haber PS; Stockler M; Lintzeris N; Simes J; McGregor I; Olver I; Allsop DJ; Gedye C; Kirby AC; Morton RL; Fox P; Clarke S; Briscoe K; Aghmesheh M; Wong N; Walsh A; Hahn C; Grimison P
BMJ Open; 2018 Sep; 8(9):e020745. PubMed ID: 30209152
[TBL] [Abstract][Full Text] [Related]
3. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
Duran M; Pérez E; Abanades S; Vidal X; Saura C; Majem M; Arriola E; Rabanal M; Pastor A; Farré M; Rams N; Laporte JR; Capellà D
Br J Clin Pharmacol; 2010 Nov; 70(5):656-63. PubMed ID: 21039759
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy.
Smith LA; Azariah F; Lavender VT; Stoner NS; Bettiol S
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009464. PubMed ID: 26561338
[TBL] [Abstract][Full Text] [Related]
5. Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial.
Sukpiriyagul A; Chartchaiyarerk R; Tabtipwon P; Smanchat B; Prommas S; Bhamarapravatana K; Suwannarurk K
Int J Womens Health; 2023; 15():1345-1352. PubMed ID: 37608911
[TBL] [Abstract][Full Text] [Related]
6. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
8. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
Wu Z; Fu X; Jing H; Huang W; Li X; Xiao C; Li Z; You F
J Ethnopharmacol; 2024 May; 325():117853. PubMed ID: 38341113
[TBL] [Abstract][Full Text] [Related]
9. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
11. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
Pérol D; Provençal J; Hardy-Bessard AC; Coeffic D; Jacquin JP; Agostini C; Bachelot T; Guastalla JP; Pivot X; Martin JP; Bajard A; Ray-Coquard I
BMC Cancer; 2012 Dec; 12():603. PubMed ID: 23244208
[TBL] [Abstract][Full Text] [Related]
12. Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer.
Alderman B; Hui D; Mukhopadhyay S; Bouleuc C; Case AA; Amano K; Crawford GB; de Feo G; Sbrana A; Tanco K; To J; Garsed J; Davis M
Support Care Cancer; 2022 Dec; 31(1):39. PubMed ID: 36525085
[TBL] [Abstract][Full Text] [Related]
13. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
14. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
15. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
17. Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: A survey of the status in the chapters of the European Pain Federation.
Krcevski-Skvarc N; Wells C; Häuser W
Eur J Pain; 2018 Mar; 22(3):440-454. PubMed ID: 29134767
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy.
Serafimovska T; Darkovska-Serafimovska M; Stefkov G; Arsova-Sarafinovska Z; Balkanov T
Folia Med (Plovdiv); 2020 Dec; 62(4):668-678. PubMed ID: 33415919
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
20. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
